CD274 and neoplasm: The included trials utilized varying PD-L1 evaluation metrics, such as CPS, tumor proportion score (TPS), and tumor area positivity (TAP), with different cutoff values (e.g., CPS ≥ 1 vs. CPS ≥ 10, TPS ≥ 1%) (11, 15, 22).